These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38845788)

  • 21. Dengue vaccine: an update.
    Huang CH; Tsai YT; Wang SF; Wang WH; Chen YH
    Expert Rev Anti Infect Ther; 2021 Dec; 19(12):1495-1502. PubMed ID: 34182875
    [No Abstract]   [Full Text] [Related]  

  • 22. Targets and strategies for vaccine development against dengue viruses.
    Wang WH; Urbina AN; Lin CY; Yang ZS; Assavalapsakul W; Thitithanyanont A; Lu PL; Chen YH; Wang SF
    Biomed Pharmacother; 2021 Dec; 144():112304. PubMed ID: 34634560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Development of immunizing agents against dengue].
    López Antuñano FJ; Mota J
    Rev Panam Salud Publica; 2000 May; 7(5):285-92. PubMed ID: 10893968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
    Kanesa-thasan N; Sun W; Kim-Ahn G; Van Albert S; Putnak JR; King A; Raengsakulsrach B; Christ-Schmidt H; Gilson K; Zahradnik JM; Vaughn DW; Innis BL; Saluzzo JF; Hoke CH
    Vaccine; 2001 Apr; 19(23-24):3179-88. PubMed ID: 11312014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dengue, zika, chikungunya and the development of vaccines].
    Kantor IN
    Medicina (B Aires); 2018; 78(1):23-28. PubMed ID: 29360072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.
    Gunale B; Farinola N; Yeolekar L; Shrivastava S; Girgis H; Poonawalla CS; Dhere RM; Arankalle V; Chandra Mishra A; Mehla R; Kulkarni PS
    Vaccine; 2023 Aug; 41(38):5614-5621. PubMed ID: 37532611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dengue: Status of current and under-development vaccines.
    Redoni M; Yacoub S; Rivino L; Giacobbe DR; Luzzati R; Di Bella S
    Rev Med Virol; 2020 Jul; 30(4):e2101. PubMed ID: 32101634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.
    Magnani DM; Silveira CGT; Ricciardi MJ; Gonzalez-Nieto L; Pedreño-Lopez N; Bailey VK; Gutman MJ; Maxwell HS; Domingues A; Costa PR; Ferrari L; Goulart R; Martins MA; Martinez-Navio JM; Fuchs SP; Kalil J; Timenetsky MDC; Wrammert J; Whitehead SS; Burton DR; Desrosiers RC; Kallas EG; Watkins DI
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28878078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamics of susceptibility and transmissibility of the live, attenuated, candidate vaccines dengue-1 PDK13, dengue-3 PGMK30F3, and dengue-4 PDK48 after oral infection in Aedes aegypti.
    Jirakanjanakit N; Khin MM; Yoksan S; Bhamarapravati N
    Am J Trop Med Hyg; 1999 Oct; 61(4):672-6. PubMed ID: 10548309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity.
    Mintaev RR; Glazkova DV; Orlova OV; Ignatyev GM; Oksanich AS; Shipulin GA; Bogoslovskaya EV
    Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
    Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
    Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
    Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
    J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a single dose, live-attenuated 'tetravalent dengue vaccine' in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial.
    Mohanty L; Prabhu M; Kumar Mishra A; Purty AJ; Kanungo R; Ghosh G; Prahan Kumar R; Newton Raj A; Bhushan S; Kumar Jangir M; Gupta A; Bhakri A
    Vaccine X; 2022 Apr; 10():100142. PubMed ID: 35252836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiologic Trends of Dengue in U.S. Territories, 2010-2020.
    Ryff KR; Rivera A; Rodriguez DM; Santiago GA; Medina FA; Ellis EM; Torres J; Pobutsky A; Munoz-Jordan J; Paz-Bailey G; Adams LE
    MMWR Surveill Summ; 2023 May; 72(4):1-12. PubMed ID: 37192141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control.
    Thavara U; Tawatsin A; Nagao Y
    Epidemiol Infect; 2014 Jun; 142(6):1245-58. PubMed ID: 23925059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
    Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
    Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
    Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
    Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dengue Vaccination: Towards a New Dawn of Curbing Dengue Infection.
    Jain S; Vimal N; Angmo N; Sengupta M; Thangaraj S
    Immunol Invest; 2023 Nov; 52(8):1096-1149. PubMed ID: 37962036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.